KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent…

Overview of attention for article published in Journal of Clinical Oncology, May 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news: 3 news outlets

twitter: 2 X users

Readers on

mendeley: 12 Mendeley

So far, Altmetric has seen 3 news stories from 3 outlets.

Westin Highlights Key Clinical Trial Updates from the 2023 ASCO Annual Meeting in Gynecologic Oncology

OncLive, 18 Jul 2023

Shannon Westin, MD, MPH Results from the phase 3 KEYNOTE-826 trial (NCT03635567), SHAPE trial (NCT01658930), and phase 3…

Les données de KEYNOTE-826 confirment le bénéfice de survie de l’ajout de pembrolizumab dans le cancer du col de l’utérus

Nouvelles du monde, 16 Jun 2023

L’ajout de pembrolizumab (Keytruda) à la chimiothérapie avec ou sans bevacizumab (Avastin) pour le traitement de première ligne…

KEYNOTE 826 data confirm survival benefit of adding pembrolizumab in cervical cancer

NewsBeezer, 16 Jun 2023

The addition of pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) for the first-line treatment of…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.